358 related articles for article (PubMed ID: 33910953)
1. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice.
Reinharz V; Ishida Y; Tsuge M; Durso-Cain K; Chung TL; Tateno C; Perelson AS; Uprichard SL; Chayama K; Dahari H
J Virol; 2021 Jun; 95(14):e0049220. PubMed ID: 33910953
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
3. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
Colombatto P; Civitano L; Bizzarri R; Oliveri F; Choudhury S; Gieschke R; Bonino F; Brunetto MR;
Antivir Ther; 2006; 11(2):197-212. PubMed ID: 16640101
[TBL] [Abstract][Full Text] [Related]
4. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
5. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
Kosaka K; Hiraga N; Imamura M; Yoshimi S; Murakami E; Nakahara T; Honda Y; Ono A; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Aikata H; Ochi H; Ishida Y; Tateno C; Yoshizato K; Sasaki T; Chayama K
Biochem Biophys Res Commun; 2013 Nov; 441(1):230-5. PubMed ID: 24140055
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B.
Yeh ML; Huang JF; Dai CY; Yu ML; Chuang WL
Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):779-785. PubMed ID: 31593639
[No Abstract] [Full Text] [Related]
7. Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.
Ishida Y; Chung TL; Imamura M; Hiraga N; Sen S; Yokomichi H; Tateno C; Canini L; Perelson AS; Uprichard SL; Dahari H; Chayama K
Hepatology; 2018 Aug; 68(2):473-484. PubMed ID: 29572897
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Ingiliz P; Valantin MA; Thibault V; Duvivier C; Dominguez S; Katlama C; Poynard T; Benhamou Y
Antivir Ther; 2008; 13(7):895-900. PubMed ID: 19043923
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
10. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
[TBL] [Abstract][Full Text] [Related]
11. Preliminary study on the efficacy and safety of lamivudine and interferon alpha therapy in decreasing serum HBV DNA level in HBV positive transgenic mice during pregnancy.
Li D; Xu DZ; Choi BC; Men K; Zhang JX; Lei XY; Yan YP
J Med Virol; 2005 Jun; 76(2):203-7. PubMed ID: 15834875
[TBL] [Abstract][Full Text] [Related]
12. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P; Viganò M; Di Costanzo GG; Sagnelli E; Fasano M; Di Marco V; Boninsegna S; Farci P; Fargion S; Giuberti T; Iannacone C; Regep L; Massetto B; Facchetti F; Colombo M;
Gut; 2013 Feb; 62(2):290-8. PubMed ID: 22859496
[TBL] [Abstract][Full Text] [Related]
13. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis B infection using interferon.
Guan R
Med J Malaysia; 2005 Jul; 60 Suppl B():28-33. PubMed ID: 16108170
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with pegylated interferon prevents emergence of lamivudine mutants in lamivudine-naive patients: a pilot study.
Villa E; Lei B; Taliani G; Graziosi A; Critelli R; Luongo M; Gennari W; Bianchini M; Ferretti I
Antivir Ther; 2009; 14(8):1081-7. PubMed ID: 20032538
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection.
Song J; Zhou Y; Li S; Wang B; Zheng X; Wu J; Gibbert K; Dittmer U; Lu M; Yang D
PLoS One; 2014; 9(3):e90977. PubMed ID: 24618716
[TBL] [Abstract][Full Text] [Related]
18. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
[TBL] [Abstract][Full Text] [Related]
19. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
[TBL] [Abstract][Full Text] [Related]
20. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection.
Marinos G; Naoumov NV; Williams R
Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
